| Brian A White, AA | |
|
4025 N 92nd St, Wauwatosa, WI 53222-1613 | |
| (414) 358-5431 | |
| Not Available |
| Full Name | Brian A White |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology Assistant |
| Experience | 11 Years |
| Location | 4025 N 92nd St, Wauwatosa, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528407376 | NPI | - | NPPES |
| 100030939 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | 35 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aurora Medical Center - Grafton | Grafton, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aurora Medical Group, Inc. | 6709794258 | 3207 |
News Archive
To learn what different cells do, scientists switch them on and off and observe what the effects are. There are many methods that do this, but they all have problems: too invasive, or too slow, or not precise enough. Now, a new method to control the activity of neurons in mice, devised by scientists at Rockefeller University and Rensselaer Polytechnic Institute, avoids these downfalls by using magnetic forces to remotely control the flow of ions into specifically targeted cells.
A team of researchers from the University of California, San Diego School of Medicine, Oregon Health & Science University and Salk Institute for Biological Studies has shown for the first time that stem cells created using different methods produce differing cells.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the signing of an exclusive, worldwide, contract research collaboration agreement with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatology and inflammation.
Beneficial Alzheimer's therapies that don't use drugs, and an update on prevention efforts, are the focus of the second day's plenary sessions at the 25th International Conference of Alzheimer's Disease International, March 12, 2010 at the Grand Hotel Palace, Thessaloniki, Greece.
U.S. Department of Health and Human Services (HHS) Secretary Kathleen Sebelius released the following statement today on WellPoint's announcement that it intends to end the practice of rescinding patients' coverage in advance of the Affordable Care Act's requirement that insurers stop this practice starting this fall. WellPoint's announcement comes after Secretary Sebelius sent a letter on April 22 urging the company to immediately stop the practice of rescinding coverage for patients who become ill.
› Verified 5 days ago
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
To learn what different cells do, scientists switch them on and off and observe what the effects are. There are many methods that do this, but they all have problems: too invasive, or too slow, or not precise enough. Now, a new method to control the activity of neurons in mice, devised by scientists at Rockefeller University and Rensselaer Polytechnic Institute, avoids these downfalls by using magnetic forces to remotely control the flow of ions into specifically targeted cells.
A team of researchers from the University of California, San Diego School of Medicine, Oregon Health & Science University and Salk Institute for Biological Studies has shown for the first time that stem cells created using different methods produce differing cells.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the signing of an exclusive, worldwide, contract research collaboration agreement with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatology and inflammation.
Beneficial Alzheimer's therapies that don't use drugs, and an update on prevention efforts, are the focus of the second day's plenary sessions at the 25th International Conference of Alzheimer's Disease International, March 12, 2010 at the Grand Hotel Palace, Thessaloniki, Greece.
U.S. Department of Health and Human Services (HHS) Secretary Kathleen Sebelius released the following statement today on WellPoint's announcement that it intends to end the practice of rescinding patients' coverage in advance of the Affordable Care Act's requirement that insurers stop this practice starting this fall. WellPoint's announcement comes after Secretary Sebelius sent a letter on April 22 urging the company to immediately stop the practice of rescinding coverage for patients who become ill.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian A White, AA 4025 N 92nd St, Wauwatosa, WI 53222-1613 Ph: (414) 358-5431 | Brian A White, AA 4025 N 92nd St, Wauwatosa, WI 53222-1613 Ph: (414) 358-5431 |
News Archive
To learn what different cells do, scientists switch them on and off and observe what the effects are. There are many methods that do this, but they all have problems: too invasive, or too slow, or not precise enough. Now, a new method to control the activity of neurons in mice, devised by scientists at Rockefeller University and Rensselaer Polytechnic Institute, avoids these downfalls by using magnetic forces to remotely control the flow of ions into specifically targeted cells.
A team of researchers from the University of California, San Diego School of Medicine, Oregon Health & Science University and Salk Institute for Biological Studies has shown for the first time that stem cells created using different methods produce differing cells.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the signing of an exclusive, worldwide, contract research collaboration agreement with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatology and inflammation.
Beneficial Alzheimer's therapies that don't use drugs, and an update on prevention efforts, are the focus of the second day's plenary sessions at the 25th International Conference of Alzheimer's Disease International, March 12, 2010 at the Grand Hotel Palace, Thessaloniki, Greece.
U.S. Department of Health and Human Services (HHS) Secretary Kathleen Sebelius released the following statement today on WellPoint's announcement that it intends to end the practice of rescinding patients' coverage in advance of the Affordable Care Act's requirement that insurers stop this practice starting this fall. WellPoint's announcement comes after Secretary Sebelius sent a letter on April 22 urging the company to immediately stop the practice of rescinding coverage for patients who become ill.
› Verified 5 days ago
Anna Janulewicz, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 4025 N 92nd St, Wauwatosa, WI 53222 Phone: 414-358-5431 | |
Mr. Timothy Klusman, A.A. Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 4025 N 92nd St, Wauwatosa, WI 53222 Phone: 414-358-5431 Fax: 414-358-5421 | |
Kojo Bempong, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: Ahcmg Anesthesiology, 4025 North 92nd Street, Wauwatosa, WI 53022 Phone: 414-358-5431 | |
Erin E Taylor, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 4025 N 92nd St, Wauwatosa, WI 53222 Phone: 414-358-5431 | |
John G Rippy, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 4025 N 92nd St, Wauwatosa, WI 53222 Phone: 414-358-5431 |